TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prostate cancer~* Patient must have received primary definitive local therapy to the prostate (surgery and/or radiotherapy)~* Patient was surgically or pharmacologically castrated at least 6 months prior to starting the study~* Patient must have had a previous trial of anti-androgen therapy~* Patient must have a rising PSA~* No evidence of distant metastatic disease~* ECOG performance status \< 2~* Age \>18 years~* Patients must have normal hepatic function~Exclusion Criteria:~* Patients with a history of any previous cytotoxic therapy or radionuclide therapy (such as rhenium, strontium, or samarium)~* Patients may not be receiving any other investigational agents~* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Patients receiving renal dialysis~* Patients with significant pulmonary disease who have received chronic or pulse steroid therapy within the last 3 months prior to randomization will be excluded~* Patients who have known hypersensitivity to any of the AndroGel ingredients, including testosterone that is chemically synthesized from soy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Twenty subjects will receive testosterone gel
- B (Type: PLACEBO_COMPARATOR): Twenty subjects will receive the placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact on Drinking Behaviour in Sixth-grade Students Through Changing the School Environment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Students in one of the recruited schools~* Appropriate knowledge of the German language~Exclusion Criteria:~* No signed consent of parent and of child

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 13 Years
- Healthy Volunteers: t

Study Arms:
- control (Type: NO_INTERVENTION): the range of products offered by the vending machines remains unchanged
- Intervention group 1 (Type: OTHER): vending machines will be re-equipped to contain 60% drinks containing a maximum of 6.7g sugar/100ml, 20% drinks containing more than 6.7g sugar/100ml and 20% water
- Intervention group 2 (Type: OTHER): In the second intervention group, the vending machines offer 80% water and 20% products with a maximum of 6.7g sugar/100ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients with recently diagnosed invasive or in situ breast cancer by core needle biopsy or FNA (confirmed at MSKCC) prior to enrollment.~* Patients planning treatment with mastectomy at MSKCC.~* Patients 21 years old or older.~* Patients who had or are having a breast MRI within 30 days or less of PEM.~* Patients who had or are having a digital mammogram.~Exclusion Criteria:~* Patients who are pregnant or breast feeding.~* Patients with prior radiation therapy or endocrine therapy.~* Patients who had a prior lumpectomy.~* Patients who are diabetic.~* Patients with moderate to end stage kidney disease.~* Patients who have a contraindication to MRI (i.e. pacemaker, metallic implants, etc).

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRI and PEM scans (Type: EXPERIMENTAL): All consenting patients who are to have staging breast MRI, will be offered 18FDG PEM (Positron Emission Mammography) within 30 days. If the patient had a previous breast MRI that was done within 30 days at an outside institution, this MRI can be used if a radiologist determines that it is an adequate study. The surgery date will not be affected by the additional PEM evaluation. All imaging will be done and reviewed by MSKCC breast imagers. MRI and PEM findings suggestive of malignancy will be prospectively recorded in both the ipsilateral and contralateral breast.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed small cell lung cancer (SCLC)~  * Recurrent extensive stage disease~ * No mixed histology~* Measurable disease~  * At least 1 bidimensionally measurable, non-central nervous system (CNS), indicator lesion confirmed by CT scan or MRI~* Sensitive disease~  * Responded to prior first-line therapy AND relapsed ≥ 60 days after response (90 days after initiation of first-line therapy)~* Eligible for high-dose chemotherapy~* No symptomatic brain metastases affecting performance status~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Eastern Cooperative Oncology Group (ECOG) 0-2~Life expectancy~* At least 2 months~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9.0 g/dL~* Hematocrit \> 35% (without transfusion)~Hepatic~* Serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) ≤ 2 times normal\*~* Alkaline phosphatase ≤ 2 times normal\*~* Bilirubin ≤ 2.0 mg/dL~* Albumin \> 2.5 g/dL~* Hepatitis B surface antigen negative~* No significant hepatic disease Note: \*≤ 5 times upper limit of normal if liver metastases are present~Renal~* Creatinine clearance ≥ 40 mL/min~Cardiovascular~* No history of cardiac arrhythmias~* No congestive heart failure~* No ischemic heart disease~* No stroke or other embolic disease requiring daily treatment that would preclude study participation~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after study participation~* HIV negative~* No known seizure disorder~* No active infection requiring systemic therapy within the past 2 weeks~* No known hypersensitivity to topotecan hydrochloride~* No medical or psychiatric condition that would preclude study participation~* No other malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage A low-grade prostate cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~* More than 4 weeks since prior antineoplastic and/or myelosuppressive chemotherapy~* No more than 1 prior chemotherapy regimen (except for adjuvant chemotherapy) for SCLC~* No prior topotecan hydrochloride~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* More than 2 months since prior investigational agent~* No other concurrent investigational agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Patient Tolerability and Efficacy of Bowel Preparation With Split Dose Picosalax vs. Split Dose PEG

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All male and non-pregnant female patients between ages 18 and 75 years old who require outpatient colonoscopy~Exclusion Criteria:~* ileus or bowel obstruction, previous colorectal surgery, ascites, recognized renal impairment, defined as GFR less than normal in 3 months prior to enrollment, active inflammatory bowel disease, insulin dependent diabetes, pregnancy, or recent (\<6 months) myocardial infarction or unstable angina

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Split dose PEG (Type: EXPERIMENTAL): Patients randomized to the Polyethylene Glycol (PEG) group will be instructed to ingest 2L of bowel preparation the night before their colonoscopy (starting at 7PM), as well as 1.5-2L of carbohydrate-electrolyte rehydration solution. The following day they will be instructed to ingest the remaining 2L of bowel preparation and must finish ingesting the entire preparation at least 4 hours prior to the scheduled colonoscopy.
- Split dose Picosalax (Type: EXPERIMENTAL): Patients randomized to the Picosalax (P/MC) group will be instructed to mix one sachet in 150mL of water and ingest the entire mixture at 7PM the night before their colonoscopy. In addition, they will be instructed to ingest 1.5-2L of carbohydrate-electrolyte rehydration solution after they consume the P/MC sachet. The following day they will mix the second sachet in 150mL of water and must finish ingesting the entire preparation at least 4 hours prior to the scheduled colonoscopy. They will also be instructed to drink additional carbohydrate-electrolyte rehydration solution after they ingest the P/MC sachet.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: OMILQ: Osteopathic Manipulation to Increase Lactation Quantity (OMILQ)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 - 40~2. Between 2 and 28 weeks postpartum from a live infant birth weighing at least 2500g~3. Desire to exclusively breastfeed~4. Able to provide informed consent~5. Available for the duration of the study~6. 1 hour milk volume of less than 1oz (or 2oz for twins)~7. All current nurslings are the same age~Exclusion Criteria:~1. Current use of domperidone~2. Current use of metoclopramide~3. Current use of silymarin~4. History of breast surgery~5. Current malignancy~6. Current pulmonary embolism or deep vein thrombosis~7. Current medical condition resulting in increased intra-cranial pressure~8. History of insufficient glandular tissue (IGT)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Osteopathic Manipulation (Type: EXPERIMENTAL): This research will be carried out as a prospective, non-randomized pilot study in women aged 18-40 who are 2 weeks to 28 weeks postpartum.~The intervention investigated in this study is osteopathic manipulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of facial capillary malformation (port-wine stain, PWS) made by a dermatologist~* age: 12-17 years of age~* weight \> 45 kg~* lesions with a surface area \< 100 cm2~* signed consent and assent for study participation~Exclusion Criteria:~* skin breakdown overlying the malformation due to other dermatological conditions (e.g. eczema, psoriasis)~* current or treatment with laser the past 3 months~* other topical treatments used within the past 4 weeks (e.g. rapamycin, corticosteroids, calcineurin inhibitors, etc)~* known chronic renal or hepatic disorders~* known cardiovascular disorders~* other systemic medications that potentially interact with Brimonidine (opiates, chlorpromazine, methyphenidate, reserpine, etc)~* mixed capillary/ venous or lymphatic malformations~* known allergy to one of the constituents of Onreltea~* pregnancy, or sexually active subjects of child-bearing potential (CBP), unwilling to use contraception during the study (such as barrier method, or oral contraceptives).

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Onreltea ( Brimonidine) (Type: EXPERIMENTAL): All the patients enrolled in the study will apply Onreltea ( Brimonidine 0.33%) gel on the affected skin area for 12 weeks (from Day 0 to Week 12 visit).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of the SeQuent®Please in the Treatment of De-novo Stenoses Versus Taxus™Liberté™

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Clinical evidence of stable or unstable angina or a positive functional study~* Single, stenotic de novo lesion in a native coronary artery, type A or selected B1 (see 4.3.1.1 Definition of lesion types)~* Diameter stenosis \> 70% (visual estimate)~* Vessel diameter 2.5 - 3.5 mm~* Female patients can enter this study if they are post-menopausal for at least two years or have undergone hysterectomy or sterilization~* Signed patient informed consent form~* Patient's and treating physician's agree that the patient will return for all required post procedure follow-up assessments as defined in the clinical protocol~Exclusion Criteria:~* Left ventricular ejection fraction of \< 30%~* Visible thrombus proximal to the lesion~* Expection that treatment with devices other than PTCA will be required for this lesion.~* Stenosis is within a bypass graft~* Known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, paclitaxel, or a sensitivity to contrast media which cannot be adequately pre-medicated~* Other medical illness (i.e. cancer, liver disease or congestive heart failure) that may require cytostatic or radiation therapy, cause the subject to be non-compliant with the protocol, confound the data interpretation or is associated with limited life-expectancy (i.e., less than two years).~* Acute myocardial infarction within the past 72 hours of the intended treatment (de-fined as: Q wave infarction having total creatinine kinase (CK) \>3 times the upper normal limit, or CK remains elevated above hospital normal at time of treatment)~* Chronic renal insufficiency with serum creatinine \> 2.0 mg%~* Significant gastrointestinal (GI) bleed within the past six months.~* History of bleeding diathesis or coagulopathy or will refuse blood transfusions~* Extensive peripheral vascular disease that precludes safe 6 French sheath insertion and / or requires additional anti-platelet and / or anti-coagulation treatment.~* Participating in another device or drug study within the last 6 months which may inter-fere with the interpretation of results of this study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequent®Please (Type: ACTIVE_COMPARATOR): None
- Taxus™Liberté™ (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of BMAC Enhanced CABG

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age\> 18 years and ability to understand the planned treatment.~* Patients with ischemic congestive heart failure requiring by pass surgery~* Congestive heart failure with ejection fraction ≤ 40%.~* Serum bilirubin, SGOT and SGPT ≤2.5 time the upper level of normal.~* Serum creatinine \< 3.0 or no dialysis.~* NYHA performance status ≥ 3.~* Negative pregnancy test (in women with childbearing potential).~* Subject has read and signed the IRB approved Informed Consent form~* Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, Creatinine ≤ 3.0 mg / Dl, and/or no dialysis, INR ≤ 1.6 unless on Coumadin, or PTT \<1.5 x control (to avoid bleeding complications) Patients on Coumadin will be corrected prior to the procedure and must have an INR\<1.6 at the time of randomization/surgery~Exclusion Criteria:~* Female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method, or who intend to become pregnant during the tenure of this study.~* History of Prior Radiation Exposure for oncological treatment.~* History of Bone Marrow Disorder (especially NHL, MDS) that prohibit transplantation.~* History of abnormal Bleeding or Clotting.~* History of Liver Cirrhosis.~* Acute Myocardial Infarction \< 4 weeks from treatment date.~* Known active malignancy or results outside of normal limits from the following tests: PAP, Chest X-ray, PSA, Mammogram, Hemoccult unless follow-up studies reveal patient to be cancer free.~* Active clinical infection being treated by antibiotics within one week of enrollment~* Terminal renal failure with existing dependence on dialysis~* Inability or unwillingness to comply with the treatment protocol, follow-up, research tests, or give consent.~* Unable to have 250cc bone marrow harvested.~* Medical risk that precludes anesthesia or ASA Class 5~* History of ventricular arrhythmia if AICD is not present.~* History of ventricular aneurysm.~* Concurrent surgery such as CABG with valve surgery.~* Minimally Invasive bypass surgery~* Life expectancy \<6 months due to concomitant illnesses~* Treatment with immunosuppressant drugs (including Prednisone \> 5 mg per day)~* Patients undergoing urgent by pass surgical procedure~* Patients with HGB A1C \> 8.5%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): CABG only
- BMAC enhanced CABG (Type: EXPERIMENTAL): Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Rational Approach to a Unilateral Pleural Effusion2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with recurrent pleural effusion of unknown origin after a first pleural tap according to BTS guidelines.~2. Indication for thoracoscopy according to BTS guidelines.~3. Patients accept further investigation according to Danish and BTS guidelines.~4. Have received oral and written consent and agreed.~5. At the time of inclusion, above 18 years of age.~Exclusion Criteria:~1. Female patients: pregnancy or breastfeeding.~2. Lack of language comprehension.~3. Legally incompetent patients.~4. Life expectancy less than 3 month.~5. Contraindications to pleural tissue sampling.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CE-CT scanning (Type: ACTIVE_COMPARATOR): Contrast-enhanced CT scan of the thorax and abdomen.
- PET-CT scanning (Type: ACTIVE_COMPARATOR): Positron-emission-CT scanning (low dose without contrast) of the thorax and abdomen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Femoral Micropuncture or Routine Introducer Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing left heart catheterization with anticipated or possible percutaneous coronary intervention~Exclusion Criteria:~* Left heart cardiac catheterization purely for diagnostic purposes where percutaneous coronary intervention is not anticipated~* Catheterization utilizes primary vascular access site other than the groin~* Catheterization is intended for right heart procedure alone or combined with left and right heart procedures~* Age less than 18 years~* Patient has planned intervention or access utilizing the same groin within 14 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Micropuncture (Type: ACTIVE_COMPARATOR): None
- Standard (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy